“bioverativ” Archives

in
Entry Author Date Location
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule 11/25/19 San Francisco
Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D 05/23/19 San Francisco
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs 06/15/18 San Francisco
Bluebird’s Upgraded Gene Therapy Shows Promise For Sickle Cell Patients 06/15/18 Boston
Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More 02/02/18 National
Bio Roundup: Spark v. ICER, A Solid Revelation, T Cell Deals & More 01/26/18 National
With $20B to Spend, Sanofi, Celgene Bet Big on Hemophilia, CAR-T 01/22/18 National
Bio Roundup: Skinny Cuts, Genomic Approvals, Unfrozen FDA & More 05/26/17 National
Not Resting on Hemophilia Biz, Bioverativ Pays $400M For True North 05/23/17 Boston
With Latest Deal, Biogen Bets $120M on Remedy Pharma Stroke Drug 05/15/17 Boston
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins 02/03/17 National
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More 08/12/16 National
Page 1 of 1